CAM Capital
VC Fund
New York, United States
CAM Capital is a VC fund in New York focused on Biotechnology and Health Care. CAM Capital manages private family investments. The firm’s goal is to achieve long-term compounded growth of its portfolio using a diversified, opportunistic investment strategy. In pursuit of this goal, CAM Capital engages in both trading activities and fundamentally driven investments. Our investments span all parts of the corporate capitalstructure in both the private and public markets.###Caxton Alternative Management announced that it is changing its name to CAM Capital.###
- Total investments:
- 30
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries CAM Capital invests in
Stages CAM Capital invests in
Countries CAM Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bruce Kovner
|
|||
Scott Morenstein
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 21 (70%)
- Health Care 14 (47%)
- Therapeutics 9 (30%)
- Medical 8 (27%)
- Biopharma 5 (17%)
Stage
- Post-IPO Equity 9 (30%)
- Series B 8 (27%)
- Series A 4 (13%)
- Series C 4 (13%)
- Funding Round 2 (7%)
Country
- United States 20 (67%)
- Canada 1 (3%)
- Switzerland 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bruce Kovner
Chairman
|
Chairman | Total investments: 0 | Find email | |
|
Scott Morenstein
Managing Director
|
Managing Director | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Palvella Therapeutics
|
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | Post-IPO Equity / Dec 13, 2024 | |
Kyverna Therapeutics
|
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $60M / Series B / Aug 03, 2023 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $270M / Series C / May 16, 2022 | |
|
Kyverna Therapeutics
|
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. Their therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. | $85M / Series B / Jan 26, 2022 | |
AvengeBio
|
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts. | $45M / Series A / Jan 05, 2022 | |
Antios Therapeutics
|
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections.Antios Therapeutics was founded by Abel De La Rosa, DouglasMayers, and Idean Marvasty. | $75M / Series B / Nov 03, 2021 | |
LEXEO Therapeutics
|
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline. | $100M / Series B / Sep 09, 2021 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $100M / Series B / Jul 14, 2021 | |
AltruBio
|
AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases.AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment ofcancer and immune-related inflammatory diseases.With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs.Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics.Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. | $63M / Series A / Apr 15, 2021 | |
Arcellx
|
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we arecommitted to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. | $115M / Series C / Apr 13, 2021 | |
| See all 30 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does CAM Capital invest in?
CAM Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 30 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CAM Capital?
Public channels for CAM Capital include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CAM Capital?
The team at CAM Capital includes Bruce Kovner (Chairman) and Scott Morenstein (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
